- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06311916
Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.
Efficacy and Safety of Neoadjuvant HAIC Combined With Immunotherapy and Targeted Therapy in Patients With Resectable Intermediate-stage HCC Screened by a Multimodal Deep Learning Model: a Multicenter Randomized Controlled Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary liver cancer is one of the most common malignant tumors in the world, and more than 90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Intermediate stage (BCLC-B) HCC is heterogeneous, and there is no uniform consensus on the treatment of this stage of the tumor in Western and Chinese countries, while the European guidelines recommend liver transplantation, transarterial chemoembolization (TACE), and systemic medication as the first line of treatment. In Eastern countries, such as China, BCLC-B is further categorized into stages IIa and IIb, and surgical resection is recommended as the first-line treatment option for stage IIa, while surgical resection can also be considered for stage IIb. Retrospective studies have found that surgical resection has an overall better prognosis than non-surgical treatment. However, the rate of postoperative recurrence is higher than that of early HCC. To address this issue, new tools are urgently needed to guide the selection of appropriate treatment regimens to reduce the risk of postoperative recurrence and overall survival.
Our multidisciplinary team used deep learning technology to construct an artificial intelligence prediction model of neoadjuvant therapy benefit based on pre-treatment genetic testing data, digital pathology slides and imaging data (enhanced MRI) of 536 intermediate-stage HCC patients treated with HAIC in combination with lenvatinib and PD-1 monoclonal antibody in six centers, and external center data validated the model's good ability to identify the beneficiary population of the combination regimen ( AUC 0.89, Accuracy 0.86). The aim of this study is to study the effectiveness and safety of New-adj-Net in improving the progression of intermediate-stage HCC patients during neoadjuvant therapy and postoperative recurrence by observing the benefit of the combined neoadjuvant regimen in patients who are potentially benefited from neoadjuvant therapy and direct surgery from the perspective of precision therapy.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: WanGuang Zhang
- Phone Number: +8613886195965
- Email: wgzhang@tjh.tjmu.edu.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 18-75.
- No previous local or systemic treatment for hepatocellular carcinoma.
- Child-Pugh liver function score ≤ 7.
- ECOG PS 0-1.
- No serious organic diseases of the heart, lungs, brain, kidneys, etc.
- Enhanced MRI determines that the tumor stage is intermediate (BCLC stage B) and is safe for radical hepatectomy.
- Pathologic type of hepatocellular carcinoma confirmed by puncture biopsy.
- Multimodal Deep Learning Model Screening Based on Pathology, Imaging, and Genetic Data Suggests Benefit from HAIC in Combination with Lenvatinib and PD-1 inhibitors.
Exclusion Criteria:
- Pregnant and lactating women.
- Tumor distribution in two liver lobes, diffuse growth, or other reasons why radical R0 resection is not possible.
- Suffering from a condition that interferes with the absorption, distribution, metabolism, or clearance of the study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, impaired absorption, etc.).
- A history of gastrointestinal bleeding within the previous 4 weeks or a definite predisposition to gastrointestinal bleeding (e.g., known locally active ulcer lesions, fecal occult blood ++ or more, or gastroscopy if persistent fecal occult blood +) that has not been targeted, or other conditions that may have caused gastrointestinal bleeding (e.g., severe fundoplication/esophageal varices), as determined by the investigator.
- Active infection.
- Other significant clinical and laboratory abnormalities that affect the safety evaluation.
- Inability to follow the study protocol for treatment or follow up as scheduled.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Neoadjuvant therapy group
Patients in the neoadjuvant therapy group received neoadjuvant therapy before undergoing liver resection.
|
Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days) + Tirelizumab (First treatment with Tirelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)+ lenvatinib (Oral 8 mg or 12mg once a day depending body weight).
Assessment of tumor status and surgical safety after receiving neoadjuvant therapy, and eligible patients then underwent surgical resection.
Other Names:
|
Active Comparator: Direct surgical resection group
Patients in the control group undergoing liver resection directly.
|
Direct liver resection or laparoscopic liver resection depending on tumor status.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease-free survival
Time Frame: From date of include in this research until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 60 months.
|
DFS defined as the time after surgical resection until tumor recurrence or death
|
From date of include in this research until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 60 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Assessment
Time Frame: 2 months
|
Any adverse event during treatment that is incompatible with the therapeutic purpose of the medication.
|
2 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: xiaoping Chen, Tongji Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Neoadj-Net
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HCC
-
University of PisaAzienda Ospedaliera Città della Salute e della Scienza di Torino; Fondazione... and other collaboratorsRecruiting
-
Seoul National University HospitalPhilips HealthcareCompleted
-
Huazhong University of Science and TechnologyUnknown
-
Taipei Medical University WanFang HospitalTerminated
-
Leiden University Medical CenterMedtronic; ZonMw: The Netherlands Organisation for Health Research and Development and other collaboratorsCompletedHCC | Early Stage HCCNetherlands
-
Qianfoshan HospitalNot yet recruiting
-
Xuhua DuanRecruiting
-
Ain Shams UniversityCompleted
-
Shenyang Tenth People's HospitalBeijing Tsinghua Changgeng HospitalNot yet recruiting
Clinical Trials on HAIC + Tirelizumab +lenvatinib +liver resection
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingHepatocellular CarcinomaChina
-
Ruijin HospitalRecruitingHER2-negative Advanced Gastric CancerChina
-
Fundación de Investigación Biomédica - Hospital...Marcello Di MartinoCompletedMetastatic Colorectal Cancer | Metastatic Liver CancerSpain, United Kingdom, France
-
hui houNot yet recruitingLaparoscopic Liver Resection | Open Liver ResectionChina
-
Fudan UniversityNot yet recruitingLiver Metastases | Colorectal CarcinomaChina
-
Fondazione Poliambulanza Istituto OspedalieroThe Queen Elizabeth Hospital; Clinica Universidad de Navarra, Pamplona, Spain; Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands and other collaboratorsCompletedObesity | Liver Metastases | Liver CancerItaly
-
University of MilanUnknownOverall Survival | Patients Affected by Hepatocellular Carcinoma | Disease-Free SurvivalItaly
-
Oslo University HospitalHelse Sor-OstActive, not recruitingColorectal Neoplasms | Secondary Malignant Neoplasm of LiverNorway
-
Huazhong University of Science and TechnologyNot yet recruitingHepatocellular Carcinoma by BCLC StageChina
-
Fondazione Poliambulanza Istituto OspedalieroIRCCS Azienda Ospedaliero-Universitaria di Bologna; Universita di Verona; University... and other collaboratorsCompletedColorectal Cancer Metastatic | Surgical Procedure, UnspecifiedItaly